Switch to:
More From Other Websites
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for... Mar 11 2014
Amgen 4Q profit leaps 30 percent on higher sales Jan 28 2014
Amgen 4Q profit leaps 30 percent on higher sales Jan 28 2014
Amgen Q4 profit leaps 30 percent on higher sales Jan 28 2014
Amgen Q4 profit leaps 30 percent on higher sales Jan 28 2014
Best Call of 2013: Onyx Pharmaceuticals Dec 31 2013
The International Myeloma Foundation Announces Partnership with Onyx Pharmaceuticals to Support... Dec 06 2013
BioMarin: Where Biotech and Rodney Dangerfield Cross Paths Nov 26 2013
3 Monday Morning Biotech Movers Nov 25 2013
2 Biotech Stocks With Strong Buyout Potential Nov 25 2013
U.S. FDA Approves NEXAVAR® (sorafenib) for the Treatment of Patients with Locally Recurrent or... Nov 22 2013
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of... Nov 07 2013
Karyopharm Therapeutics IPO Looks Promising Nov 06 2013
Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers Oct 02 2013
ONYX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Triggering... Oct 01 2013
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer Oct 01 2013
Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock Sep 30 2013
Amgen's 10 Billion Dollar Molecule Sep 30 2013


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide